- Location
- Northern California, USA
First published study that I am aware of that followed kids on remicade for 5 years. Found linear growth catch up to normal by year 3 in Tanner stage 1/2 patients who started remicade within 18 months of diagnosis. Found sustained response improved by simultaneous use of immunomodulator for >= 30 months. Study authors from Toronto, Canada. I also posted this in the Research thread.
Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease.
http://www.ncbi.nlm.nih.gov/pubmed/24865777
CONCLUSIONS:
These data demonstrate sustained effectiveness of infliximab in children and adolescents with luminal CD. Durability of response is increased by concomitant immunomodulation. Clinical response is associated with enhanced linear growth, particularly when therapy is initiated early.
Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease.
http://www.ncbi.nlm.nih.gov/pubmed/24865777
CONCLUSIONS:
These data demonstrate sustained effectiveness of infliximab in children and adolescents with luminal CD. Durability of response is increased by concomitant immunomodulation. Clinical response is associated with enhanced linear growth, particularly when therapy is initiated early.